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BACKGROUND  
Radioembolization is a new tool for the treatment of hepatic tumors that consists in the 
injection of biocompatible microspheres carrying radioisotopes into the hepatic artery or 
its branches. 
 
METHODS  
We have performed radioembolization in 78 patients with hepatic tumors using resin-
based microspheres loaded with yttrium-90. All patients were previously evaluated to 
minimize the risk of hazardous irradiation to nontarget organs and to obtain the data 
needed for dose calculation. 
 
RESULTS  
We report a complication found in three cases (3.8%) that consists of abdominal pain 
resulting from gastroduodenal lesions and that had a chronic, insidious course. 
Microscopically, microspheres were detected in the specimens obtained from all 
affected gastric areas. Since these gastroduodenal lesions do not appear when 
nonradiating microspheres are injected in animals, lesions are likely to be due to 
radiation and not to an ischemic effect of vascular occlusion by spheres. 
 
CONCLUSIONS  
We believe that a pretreatment evaluation that includes a more thorough scrutiny of the 
hepatic vascularization in search of small collaterals connecting to the gastroduodenal 
tract can help prevent this awkward complication. 
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INTRODUCTION 
 
Radioembolization is a new tool for the treatment of hepatic tumors. It consists of the 
delivery of resin or glass microspheres loaded with radioactive isotopes into the hepatic 
artery or its branches. SIR-Spheres® (Sirtex Medical Europe, Bonn, Germany) are resin 
microspheres of around 35 microns in diameter loaded with yttrium-90, a beta-emitter 
with a halflife of about 64 h and an average penetration in tissues of around 2.4 mm. 
Microspheres are embolized into the hepatic artery and they become lodged within the 
microvasculature of the tumor where they emit the beta radiation (1). SIR-Spheres 
allow, on average, 200–300 Gy to be delivered to liver tumors irrespective of their 
number, size, and location (2). We have retrospectively reviewed all symptomatic 
gastroduodenal lesions appearing after liver radioembolization in the largest population 
of patients so far studied. 
 
 
RADIOEMBOLIZATION PROCEDURE 
 
All patients give signed informed consent before pretreatment evaluation, which is 
designed to minimize the risk of hazardous irradiation to nontarget organs and to obtain 
the data needed for dose calculation. Evaluation starts with a comprehensive 
angiographic study aimed at detecting any possible variation of arterial liver 
distribution, identifying vessels that give arterial blood supply to every liver tumor 
nodule and those other vessels that may give access to extrahepatic organs, and 
evaluating portal vein blood flow. Then, the gastroduodenal artery (GDA) and any other 
collateral vessel that may result in microspheres being lodged into the gastrointestinal 
area are occluded by standard angiographic methods (normally endovascular coils). The 
GDA was occluded at evaluation in every case with two exceptions: those patients that 
already had the GDA occluded due to previous intra-arterial chemotherapy and those 
patients in whom the microspheres were injected from either the right hepatic artery or 
the left hepatic artery (lobar treatments) with the tip of the catheter placed far enough 
from the origin of the GDA. And finally, with the tip of the catheter placed in the 
position intended for treatment, Tc99-radiolabeled macroaggregates of albumin (MAA) 
are injected and subsequently imaged to determine the degree of shunt to the lung, to 
detect any possible “nontarget locations” of microspheres in the GI tract, and to evaluate 
the relative amount of activity going to the liver tumors and the nontumoral liver. One 
to two weeks later and with the tip of the catheter placed in the same position used for 
MAA test, the calculated activity of microspheres is injected. Following treatment, 
patients remain in hospital overnight and supportive therapy generally consists of (a) 
pre- and post-therapy IV hydration, (b) prophylaxis of gastritis with a proton pump 
inhibitor starting the day of treatment and continued for 4 wk, (c) a low-dose of methyl-
prednisolone given for 4 wk starting on the day of treatment, and (d) antiemetics (e.g., 
ondansetron) and analgesics (e.g., paracetamol or tramadol) on demand. 
 
 
PATIENTS 
 
From September 2003 to June 2006, we have performed 80 radioembolization 
procedures in 78 patients with primary and secondary liver tumors. Three of them 
(3.8%) presented significant abdominal pain 8–16 wk after the infusion of Sir-Spheres 
and underwent an upper endoscopy during the follow-up. 
Case 1 
A 56-yr-old woman presented in 2003 having a papillary renal cell carcinoma with liver 
and pulmonary metastasis. Immunotherapy with interleukin 2 was started after 
nephrectomy but failed to induce tumor response. One year later, radioembolization was 
performed. Angiography and MAA test showed no contraindications for 
radioembolization, with an extrahepatic shunt of 5.85%. A small gastric artery was 
occluded before microsphere injection at the same procedure and 1.11 GBq of SIR-
Spheres were injected into the common hepatic artery. Twelve hours after the injection, 
the patient complained of right upper-abdominal pain, nausea, and vomiting. She 
received analgesia and prokinetics and the symptoms progressively improved but pain 
did not subside. Four months later, mild upper-abdominal pain still remained. 
 
A FDG-PET-CT scan done for evaluation of tumor response showed a hypermetabolic 
area located in the pylorus (Fig. 1) suggestive of an inflammatory process. An upper 
endoscopy was then performed that revealed two ulcers in the duodenal bulb (Fig. 2). 
Urease test was negative and biopsies showed that the structure of all tissue layers was 
fairly well preserved, and that dark spheres were present in the submucosa (Fig. 3). 
Therapy with esomeprazole (40 mg daily) and pentoxifylline (thrice daily) resulted in 
symptom improvement and was maintained for 1 yr. On follow-up gastroscopy (3 
months after the first one), a cicatricial area, probably related to previous ulcers, was 
apparent in the duodenal bulb, and close to it, a fibrin-coated ulcer of approximately 1 
cm in diameter (Fig. 4). 
 
Case 2 
A 54-yr-old man presented in 2005 with small bowel neuroendocrine tumor and liver 
metastasis. Resection of the primary tumor was performed in 2002 and he subsequently 
received 4 courses of intra-arterial oxaliplatin and oral capecitabine. In May 2005, he 
was evaluated for radioembolization. No contraindications were found on angiography 
and MAA test, with an extrahepatic shunt of 5.23%. The GDA was occluded before 
microsphere injection at the same procedure and 2.76 GBq of SIR-Spheres were 
subsequently injected into the common hepatic artery. Intense pain developed during 
the procedure that required narcotics. Two months later, he was admitted because of 
abdominal pain, nausea, vomiting, and weight loss, and an upper endoscopy showed a 
wide ulcerated area involving the gastric antrum, lesser curvature, pylorus, and 
duodenal bulb (Fig. 5). Scattered fibrin-covered ulcers could be individualized within 
this area. Biopsy showed small spheres located inside the vessels (Fig. 6). He was 
placed on pantoprazole (40 mg daily), and 10 months later he still had abdominal 
discomfort to some extent. 
 
Case 3 
A 48-yr-old man with nonresectable liver metastasis from colorectal cancer resected in 
2004 had been treated with hepatic intra-arterial chemotherapy from February 2005 to 
March 2005 with no hepatic response. In May 2005, he was evaluated for 
radioembolization. No contraindications were found in the angiogram and MAA test 
with an extrahepatic shunt of 10.1%. The GDA was occluded before microsphere 
injection at the same procedure and 1.11 GBq of SIR-Spheres were injected into the 
common hepatic artery. Three months later during a routine evaluation, he complained 
of abdominal pain, nausea, and vomiting that had started 20 days after 
radioembolization. An upper endoscopy showed a large, welldelimited ulcer spreading 
from the posterior wall of the gastric body to the pylorus (Fig. 7) that was actively 
bleeding in the antrum. Treatment with esomeprazole (40 mg twice daily) and 
pentoxifylline (thrice daily) was followed by symptom improvement. A month later, a 
follow-up endoscopy showed that the surface of the ulcer was irregular with a big 
denudated area on which small islets of normal mucosa could be found, as if the mucosa 
was trying to regenerate (Fig. 8). 
 
 
DISCUSSION 
 
External irradiation of the stomach can cause severe gastritis and ulceration, which can 
lead to fatal bleeding and perforation (3). Most of the information about the tolerance 
dose of the stomach to radiation comes from clinical studies of radiotherapy in the 
treatment of Hodgkin’s disease and testicular tumors (4), when the stomach is irradiated 
incidentally together with the upper abdominal lymph nodes. These studies have shown 
that a larger fraction size and a higher total dose are related to a higher rate of late 
radiation complications (4, 5). And in a rat model of radiation-induced gastric injury, 
animals that received between 25 and 28.5 Gy showed erosive and ulcerative gastritis 
(6). The spectrum of nonacute manifestations of radiation-induced GI lesions include 
dyspepsia, atrophic gastritis, and ulceration (7). 
  
We have found a 3.8% (3/78) incidence of symptomatic gastroduodenal ulcerations 
among patients receiving radioembolization for the treatment of liver tumors. This 
figure compares favorably with the only experience published so far (13%, meaning 4 
out of 30 patients) (2). The difference is likely to be due to a more comprehensive 
angiographic search of small collateral vessels connecting the hepatic artery with the GI 
tract with the help of a procedure that we have routinely performed lately. Planar 
images obtained after MAA injection, which is all that is needed to calculate lung shunt, 
were replaced by SPECT. And SPECT scan was then fused with the corresponding 
abdominal image (either CT or MRI) to improve the localization of activity both in the 
liver and in surrounding areas. This technique allows gastric uptake of MAA to be more 
clearly identified (Fig. 9). And since the routine implementation of this technique, we 
have not had any other gastroduodenal complication. Furthermore, in our opinion, it is 
absolutely mandatory to occlude the GDA in every case when treatment is performed in 
a whole-liver fashion from the proper or the common hepatic artery (8). Moreover, 
close attention has to be paid the day of the treatment to small collaterals arising from 
the common hepatic artery that may appear only after occlusion of the GDA. 
 
Yet, we have retrospectively obtained and reviewed such fusion images from the cases 
here presented, and no significant activity was detected in the gastroduodenal area. The 
early onset of pain in some of our patients raises the possibility that plugged spheres 
might reduce blood flow due to occlusion of the vessels. Infrequently, there could also 
be a vessel spasm attributable to the catheter stimulus. Small collaterals might also 
develop during the time between evaluation and injection. After embolization of the 
GDA, there can be hypertrophy of the pyloric artery, which might result in unnoticed 
reflux of microspheres during the procedure. 
 
From a mechanistic perspective, gastroduodenal lesions after radioembolization can 
result from ischemia, radiation, or both. The extent and homogeneity of large ulcers 
argues in favor of an ischemic effect since once would expect sphere deposition to be 
more heterogeneous. But gastroduodenal ulcers are not a common complication after 
chemoembolization for the treatment of hepatocellular carcinoma even when collateral 
occlusion is not performed earlier (9). We have studied the distribution and effects of 
“cold” microspheres (not containing Y-90) after massive injection into the hepatic 
artery of pigs without occluding collaterals. As shown in Figure 10, microspheres are 
located in the submucosa but no microscopic injury to the gastric or duodenal mucosa 
was observed. Although no animal received “hot” microspheres to be compared, this 
observation very strongly suggests that it is radiation and not ischemia that causes 
gastroduodenal ulcers after radioembolization. 
 
In summary, hepatic radioembolization carries a risk of inducing actinic gastroduodenal 
ulcers due to misplacement of radioactive microspheres in the gastrointestinal tract. This 
risk is probably lower than 5% when a very active search for collateral vessels 
connecting the hepatic arteries to the GI area is performed. But abdominal pain 
persisting or developing 1–2 months after radioembolization should prompt the 
performance of an upper endoscopy that may rule out gastric lesions. 
 
 
STUDY HIGHLIGHTS 
 
What Is Current Knowledge 
• Radioembolization can cause gastroduodenal injury.  
What Is New Here 
• Injury seems to be due to radiation and not to embolization. 
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Figure 1. Hypermetabolic activity located in the pyloris of the first patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Duodenal ulcers after radioembolization of the first patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Small sphere in the submucosa (white arrowhead) in the biopsy of the first 
patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Superficial ulcer found after 1 yr with esomeprazole and pentoxifylline (first 
patient). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Ulcer along the lesser curvature in the second patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. SIR-Spheres located inside the vessels, biopsy of the second patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Loss of gastric mucosal outface in the third patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Denudated area with small islets of normal mucosa looking as if the mucosa 
was trying to regenerate. 
 
 
 
 
 
 
Figure 9. Fusion image (SPECT-MRI) showing no gastroduodenal activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Cold spheres in the submucosa (animal model). 
